US61225M1027 - Common Stock
MONTE ROSA THERAPEUTICS INC
NASDAQ:GLUE (5/14/2024, 2:26:54 PM)
4.98
+0.03 (+0.61%)
Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. The company is headquartered in Boston, Massachusetts and currently employs 107 full-time employees. The company went IPO on 2021-06-24. The firm is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. The firm has developed a degradation platform, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product development on therapeutic targets is backed by biological and genetic rationale discovering and developing novel medicines. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer and neuroendocrine tumors.
MONTE ROSA THERAPEUTICS INC
321 Harrison Avenue, Suite 900
Boston MASSACHUSETTS
P: 16179492643
CEO: Markus Warmuth
Employees: 107
Website: https://www.monterosatx.com/
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Monte Rosa Therapeutics (NASDAQ:GLUE) just reported results for the first quart...
GLUE stock results show that Monte Rosa Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Monte Rosa Therapeutics today reported business highlights and financial results for the first quarter ending March 31, 2024. ...
Dr. Wallace will depart his role as CSO effective May 17, 2024, and will serve as a scientific advisor, including on Monte Rosa’s Scientific Advisory Board
Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer ...
Here you can normally see the latest stock twits on GLUE, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: